Skip to main content

GLP-1 RAs (Semaglutide & Tirzepatide)

What Are GLP-1 RAs?

GLP-1 receptor agonists (GLP-1 RAs) are a class of medications that mimic a natural hormone in your body called GLP-1 (glucagon-like peptide-1). Two of the most widely used GLP-1 RAs are semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro). These medications were originally developed to treat type 2 diabetes but have become widely used for weight management, metabolic health, and cardiovascular risk reduction. Tirzepatide is a dual agonist that also targets GIP (glucose-dependent insulinotropic polypeptide), making it especially potent for weight loss and metabolic improvement.

How Do They Work?

GLP-1 is a hormone naturally released by your gut after eating. It plays several important roles:

  • Signals your brain that you feel full, reducing appetite and food intake
  • Slows how quickly your stomach empties food, prolonging fullness
  • Stimulates insulin release from the pancreas in response to meals
  • Reduces glucagon (which raises blood sugar), helping lower blood sugar after eating

GLP-1 RA medications work by binding to these same receptors and activating them — amplifying all of these effects and helping your body better regulate blood sugar, appetite, and weight.

Benefits

  • Significant weight loss — among the most effective non-surgical weight loss options available; studies show 15–25% body weight reduction with consistent use
  • Blood sugar control — effectively lowers blood sugar and A1C levels in people with type 2 diabetes or prediabetes
  • Cardiovascular protection — clinical trials have shown significant reductions in heart attack, stroke, and cardiovascular death risk
  • Reduced appetite and cravings — helps control hunger signals in the brain, reducing overeating and food "noise"
  • Improved metabolic health — lowers blood pressure, improves cholesterol levels, and reduces fatty liver
  • Improved insulin sensitivity — helps the body use insulin more effectively
  • Kidney protection — emerging evidence suggests GLP-1 RAs may protect kidney function in people at risk

How to Take GLP-1 RAs

GLP-1 RAs are given as a subcutaneous injection (under the skin) once weekly. Your provider will start you at a low dose and gradually increase it over several weeks to reduce side effects.

  • Injection frequency: Once weekly, on the same day each week
  • Injection sites: Abdomen, upper thigh, or upper arm — rotate sites each week
  • Starting dose: Low (e.g., 0.25 mg for semaglutide; 2.5 mg for tirzepatide)
  • Titration: Dose is gradually increased every 4 weeks based on tolerance and response
  • Maintenance dose: Up to 2.4 mg (semaglutide) or 15 mg (tirzepatide) at full dose
  • Storage: Keep in the refrigerator until use; once opened, pens can often be kept at room temperature for a limited time — follow your specific product instructions

What to Expect

  • First few weeks: Reduced appetite and early changes in food preferences; some initial weight loss; possible GI side effects as your body adjusts
  • 1–3 months: Meaningful weight loss begins; improved blood sugar levels; GI side effects typically decrease
  • 3–6 months: Continued steady weight loss; significant metabolic improvements
  • 6–12 months: Maximum weight loss is often reached around 9–12 months; metabolic markers improve substantially
  • Ongoing: Weight maintenance requires continued therapy — weight often returns if the medication is stopped

Side Effects

The most common side effects are gastrointestinal and are typically most pronounced when starting the medication or increasing the dose:

  • Nausea — most common, especially early on; often improves within a few weeks
  • Vomiting
  • Diarrhea or constipation
  • Stomach discomfort or bloating
  • Reduced appetite (intended effect, but can sometimes be too pronounced)
  • Fatigue
  • Injection site reactions — mild redness, swelling, or itching at the injection site

Serious but rare side effects include pancreatitis (severe abdominal pain) and gallbladder issues. Contact your provider immediately for severe abdominal pain.

Tip for managing nausea: Eat smaller, slower meals; avoid high-fat or spicy foods; stay well hydrated.

Who Should Not Take GLP-1 RAs?

  • People with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2)
  • People with a history of pancreatitis
  • Women who are pregnant or breastfeeding
  • People with severe kidney or liver disease (discuss with your provider)
  • Anyone with a known allergy to semaglutide, tirzepatide, or their ingredients

Storage Instructions

  • Store unopened pens or vials in the refrigerator (36°F–46°F / 2°C–8°C)
  • Do not freeze
  • Once in use, some pens can be kept at room temperature for up to 28–56 days — follow the specific instructions for your medication
  • Keep away from direct light and heat
  • Keep out of reach of children

Frequently Asked Questions

What is the difference between semaglutide and tirzepatide?

Both are GLP-1 receptor agonists. Tirzepatide is a dual agonist — it targets both GLP-1 and GIP receptors, which gives it a more powerful effect on weight loss and blood sugar control. Clinical trials show tirzepatide produces greater average weight loss than semaglutide. Your provider will recommend the best option for your goals.

Will I regain the weight if I stop taking the medication?

Many people do regain weight after stopping GLP-1 RA therapy, as the medication affects hunger signals that return to baseline when the medication is discontinued. Long-term use or a thoughtful discontinuation plan with lifestyle changes is important. Discuss your options with your provider.

How do I manage nausea when I first start?

Nausea is most common in the first few weeks. Eating small, slow meals, avoiding rich or fatty foods, staying hydrated, and not lying down right after eating all help. Nausea typically decreases as your body adjusts.

Do GLP-1 RAs cause muscle loss?

Rapid weight loss from any cause can include loss of muscle mass. To minimize this, maintaining adequate protein intake and engaging in resistance training during your weight loss journey is strongly encouraged. Your care team can help you optimize your approach.

Can I take GLP-1 RAs if I don't have diabetes?

Yes — semaglutide (Wegovy) and tirzepatide (Zepbound) are approved specifically for chronic weight management in people with obesity or weight-related health conditions, even without diabetes.